InflaRx (IFRX) Cash from Operations (2016 - 2026)
InflaRx (IFRX) posted Cash from Operations of 8654555.75 for Q1 2026, down 58.0% sequentially from 5477523.16 in Q4 2025, and up 41.3% YoY from 6125095.85 in Q1 2025.
InflaRx (IFRX) Cash from Operations (2016 - 2026) Analysis & Trends
InflaRx has reported Cash from Operations for 11 years, with the latest figure at 8654555.75 in Q1 2026.
- Quarterly Cash from Operations rose 41.3% year-over-year to 8654555.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 33250090.41 (up 34.97% YoY) and the FY2025 annual result came in at 39898522.94, up 24.08% from the prior year.
- Cash from Operations slipped to 8654555.75 in Q1 2026 per IFRX's latest filing, from 5477523.16 in the prior quarter.
- Over five years, Cash from Operations peaked at 3192978.95 in Q3 2022 and troughed at 16152422.19 in Q1 2024.
- A 5-year average of 10452114.66 and a median of 11287469.73 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 72.82% in 2022, then sank 119.84% in 2023.
- Over 5 years, Cash from Operations stood at 5322589.69 in 2022, then sank by 119.84% to 11701228.47 in 2023, then decreased by 8.63% to 12710728.57 in 2024, then surged by 56.91% to 5477523.16 in 2025, then tumbled by 58.0% to 8654555.75 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 8654555.75, 5477523.16, and 10568212.43 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.65 Mn |
| Mar 31, 2026 | -8.65 Mn |
| Dec 31, 2025 | -5.48 Mn |
| Dec 31, 2025 | -5.48 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Jun 30, 2025 | -8.55 Mn |
| Jun 30, 2025 | -8.55 Mn |
| Mar 31, 2025 | -14.74 Mn |
| Mar 31, 2025 | -14.74 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Mar 31, 2024 | -16.15 Mn |
| Mar 31, 2024 | -16.15 Mn |
| Dec 31, 2023 | -11.70 Mn |
| Dec 31, 2023 | -11.70 Mn |